$SRPT — BUY 📊

$SRPT — BUY 📊 Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and o 🎯 Q2 2026 | Rev $1B | EPS $-3.58 vs $-0.77 🔴 💡 Consensus sees a cash-burning, declining DMD franchise with Elevidys adoption stalling; many analysts project flat revenue and continued losses. Our variant view is that Elevidys demand is inflecting, revenue can grow 20%+ annually, and management will soon guide toward profitability. 📉 Reward/Risk: 3.0:1 🏢 Business Quality: 6/10 📊 Valuation: cheap 🔮 Catalyst: Q2 2026 earnings (late July 2026) – strong Elevidys sales update and cost-cut guidance 💰 Entry: $17.53, stop $14.0, target $28.0 📊 Our read: BUY. Full analysis → https://stockduty.xyz/s/SRPT0622

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and o